Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical-stage biopharmaceutical company developing drug therapies for the eye, announces fifth patent issued in U.S. relating to its proprietary SCS™ drug delivery technology.